

This Review is part of a new thematic series on **Proteomics: New Methods, Biological Insights, and Clinical Perspectives**, which includes the following articles:

Overview: The Maturing of Proteomics in Cardiovascular Research

Proteomics: A Reality-Check for Putative Stem Cells

Divide and Conquer: The Application of Organelle Proteomics to Heart Failure

New Biomarkers in Cardiovascular Disease: Potential Impact and Strategies for Discovery

The Future of Posttranslational Modifications: From the Simple to the Complex

Jennifer E. Van Eyk, Guest Editor

Overview

The Maturing of Proteomics in Cardiovascular Research

Jennifer E. Van Eyk

Abstract: Proteomic technologies are used to study the complexity of proteins, their roles, and biological functions. It is based on the premise that the diversity of proteins, comprising their isoforms, and posttranslational modifications (PTMs) underlies biology. Based on an annotated human cardiac protein database, 62% have at least one PTM (phosphorylation currently dominating), whereas $\approx 25\%$ have more than one type of modification. The field of proteomics strives to observe and quantify this protein diversity. It represents a broad group of technologies and methods arising from analytic protein biochemistry, analytic separation, mass spectrometry, and bioinformatics. Since the 1990s, the application of proteomic analysis has been increasingly used in cardiovascular research. Technology development and adaptation have been at the heart of this progress. Technology undergoes a maturation, becoming routine and ultimately obsolete, being replaced by newer methods. Because of extensive methodological improvements, many proteomic studies today observe 1000 to 5000 proteins. Only 5 years ago, this was not feasible. Even so, there are still road blocks. Nowadays, there is a focus on obtaining better characterization of protein isoforms and specific PTMs. Consequently, new techniques for identification and quantification of modified amino acid residues are required, as is the assessment of single-nucleotide polymorphisms in addition to determination of the structural and functional consequences. In this series, 4 articles provide concrete examples of how proteomics can be incorporated into cardiovascular research and address specific biological questions. They also illustrate how novel discoveries can be made and how proteomic technology has continued to evolve. (*Circ Res.* 2011;108:490-498.)

Key Words: proteomics ■ technology ■ protein isoform ■ posttranslational modification ■ polymorphism

In this accompanying series, we explore how proteomics has matured and its application in cardiovascular research. Cardiovascular science investigates and analyzes the biological systems involved in prevention, treatment, and development of disease. It is often aimed at discovering the fundamental principles that govern or underlie the molecular disease pathways. To achieve this aim, there has been and is

a constant need for technological development. In this context, technology refers to techniques, instrumentation, and approaches/strategies that are used to solve problems that are involved in research. Each technology must, therefore, have a particular utility and use. Proteomics is a field that has been driven by the development and strategic application of technology and it continues to rapidly evolve. Proteomic

Original received October 30, 2010; revision received December 21, 2010; accepted January 14, 2011. In December 2010, the average time from submission to first decision for all original research papers submitted to *Circulation Research* was 14.5 days.

From the Johns Hopkins University Bayview Proteomic Center, Baltimore, MD.

Correspondence to Jennifer E. Van Eyk, Johns Hopkins University Bayview Proteomic Center, Rm 602, Mason F. Bldg Center Tower, Johns Hopkins University, Baltimore, MD 21239. E-mail Jvaneyk1@jhmi.edu

© 2011 American Heart Association, Inc.

Circulation Research is available at <http://circres.ahajournals.org>

DOI: 10.1161/CIRCRESAHA.110.226894




Figure 1. Schema representing the relations that are involved in discovery. Biological or clinical questions drive the development of new technologies that, when applied, will generate new hypotheses. All technology undergoes an evolution from development to finally becoming obsolete and being replaced by new or refined methods.

technologies are used to study the complexity of proteins and their biological roles, including biophysical properties, structure, and function. It is based on the premise that the diversity of proteins, comprising their isoforms, SNPs, and posttranslational modifications (PTMs), underlies biology. Protein alterations occurring because of physiological and pathological processes are reflective of changes at the gene, mRNA, miRNA and metabolite levels. Thus, the proteome consists of information from protein expression, PTMs, processing and turnover, localization and time. PTMs alter the chemical nature of an amino acid residue; which can induce changes in protein structure, activity, binding partners or subcellular localization. PTMs can add or remove a functional group (including a peptide) to a specific amino acid residue within a protein. PTMs include acetylation, amidation, methylation, sumoylation, ubiquitination, prenylation, myristoylation, *S*-glutathiolation, sulfation, *N*- and *O*-linked glycosylation, glycation, *S*-nitrosylation (SNO) (*S*-nitrosation) proteolysis and phosphorylation among others. The field of proteomics strives to observe and quantify this protein diversity. It represents a broad group of technologies and methods arising from analytic protein biochemistry, analytic separation, mass spectrometry and bioinformatics. Many technologies are synergistic and complement each other providing different data for each proteome. Proteomic technology development can be linked to specific biological and clinical questions (Figure 1). This is a reiterative situation as the application of different technologies can provide additional insights and generate new hypotheses, which is often assisted by additional methodological refinement and optimization or even creation of new technologies.

Process of Technology Development

Technology development is a process involving multiple steps (Figure 1). These steps are (1) the development phase, where the method or technology is born from trial and error experimentation; (2) prototype production, where the consistency and variability is determined; (3) early mass production, where the method requires minimal changes but is tested on a number of different situations or conditions allowing for fine-tuning; (4) regular production with standardization, where problems only rarely are experienced; (5) established method, where the wider scientific community can use the robust technology; and (6) obsolete, where the technology is

Non-standard Abbreviations and Acronyms

2DE	2D gel electrophoresis
cTnI	cardiac troponin I
GWAS	genome-wide association study
HPRD	Human Protein Reference Database
ITRAQ	isobaric tag for relative and absolute quantification
LC	liquid chromatography
MRM	multiple reaction monitoring
MS	mass spectrometry
<i>O</i>-GlcNAc	<i>O</i> -GlcNAcylation
PTM	posttranslational modification
SILAC	stable isotope labeling by amino acids in cell culture
SNP	single-nucleotide polymorphism
SNO	<i>S</i> -nitrosylation or <i>S</i> -nitrosation
TMT	tandem mass tag

no longer required or has been replaced with new methods that provides “better” data (eg, qualitative versus quantitative). Often the application of technology requires the establishment of a technical pipeline representing a number of distinct processes that are linked to solve a problem. Of equal value is the adaptation of new technology to more complex samples or experimental conditions. More often methods are initially developed using simple standards such as purified peptides or proteins. The technology then must be vetted in samples of increasing complexity. Moving the technology to a cell subproteome, intact cell or tissue can be extremely time-consuming and require considerable additional experimentation at the prototype or early mass production stages. This can also be true when changing among different subproteomes, cells and tissue types (eg, HeLa cells versus cardiac myocytes; cardiac muscle versus liver; mouse versus human). Proteomic analysis of cardiac myocytes and tissue is particularly challenging compared to many other tissues, and the reasons for this are multifactorial. Chief among them is the fact that the cardiac muscle has a large dynamic range attributable to dominance of the myofilament and mitochondrial subproteomes, and this generally requires extensive fractionation or targeted enrichment to observe low abundant proteins (eg, see elsewhere^{1–10}). This unique aspect of cardiac muscle is linked to its intrinsic physiology: the sustained, intense energetic requirements for continuous contractile activity, and the need for a minute to minute adaptation of heart rate, blood pressure, and cardiac output. Another unique aspect of the myocyte proteome is the large number of cardiac-specific isoforms and their regulation by different PTMs. An example illustrating the biological importance of protein isoforms is that of cardiac troponin (cTn)I, which regulates muscle contraction/relaxation, but unlike the skeletal muscle isoforms is phosphorylated by protein kinase A and other kinases (eg, see elsewhere^{11–14}). As well, it has been shown to undergo other types of PTMs (*O*-GlcNAcylation and proteolysis) with different pathological conditions (eg, see elsewhere^{15–18}). In many cases, a small degree of change to one of these PTMs can result in large physiological




Figure 2. The number of articles published per year using proteomics in the area of cardiac and heart research has been steadily increasing. PubMed was searched using (1) “proteomics” alone or with “proteome” and (2) either “heart or cardiac” as subjects. Articles that were not in English or were cited as reviews were excluded from the total count. There were no articles before 1998. Note, however, that when a search was carried out where “proteomics/proteome” was replaced with 2DE, articles earlier than 1998 were identified.

alterations (eg, 15% substitution of the truncated cTnI form results in $\approx 50\%$ reduced maximal force¹⁹). Because subtle PTM changes can have large functional consequences, it is necessary to develop and use techniques that can assess multiple PTMs, identify and quantify each modified residue, and be very accurate (a necessity when quantifying low abundant PTMs). In addition to the problems outlined above, the final issue for cardiac muscle proteomic studies is that there are no dividing cell culture systems for ventricular cardiomyocytes. Approaches dependent on complete saturation metabolic labeling (such as stable isotope labeling by amino acids in cell culture also known as SILAC²⁰) are therefore not possible. To detail cardiac protein changes, unique metabolic labeling strategies or alternative technologies will need to be extended or adapted.

Technology Progression in the Field of Proteomics

Since the mid- to late 1990s, the application of proteomic analysis has been increasingly used in cardiovascular research. As shown in Figure 2, there has been a continuous increase in the publication of studies using proteomic (or proteome) in PubMed. Two-dimensional gel electrophoresis (2DE), a traditional protein separation method in proteomics that combines separation of intact proteins by pI and molecular weight that was developed in the mid-1970s,^{21,22} continues to increase, but in the last few years has contributed less toward the total number of proteomic based studies. This is because of the increasing number of other protein and peptide separation methods which have been developed or refined

over the last decade along with improvements in the sensitivity and accuracy of mass spectrometers and more comprehensive bioinformatics. 2DE is among the few methods that allow the determination of quantity and potential PTM or isoform status of proteins (those that differ in the pI of the protein). It continues to be improved with methods for solubilization and loading of difficult proteins (eg, hydrophobic or basic) onto the gel, more sensitive protein stains and labeling that allow simultaneous analysis of multiple samples, and improved image alignment and quantification (reviewed elsewhere^{23–26}). Other intact protein separation methods involving liquid phases (free-flow electrophoresis), capillary electrophoresis, and liquid chromatography (LC) have similar benefits as 2DE and, interestingly, often observe a different set of proteins (reviewed elsewhere^{27–30}). This is attributable to the solubilization or separation parameters. By using more than one method in a multidimensional arrangement (off-line or in-line with mass spectrometry [MS]), an investigator can increase proteome coverage (number of proteins observed) and often protein coverage (number of peptides observed for each protein). As examples from our group, we have compared a number of different protein and peptide separation methods,^{1,9,31,32} and, in some, cases there is only $<30\%$ overlap in the proteins observed between methods. Today, many studies observe and quantify 1000 to 5000 proteins, whereas 5 years ago, this was not feasible even with extensive separation methods. To date, the type of data that proteomics can help achieve can be broken into (1) protein identification (which allows one to create a database to determine the protein composition of a specific protein complex, organelle, or cell); (2) protein quantification (either determining the relative ratio or absolute concentration); (3) identification of protein isoforms; (4) determining whether a protein has a PTM, determining the type of PTM, and identifying the specific modified amino acid residues; and finally (5) quantification of each modified residue. Certainly, the level of technical difficulty increases as one moves up to more specific and quantifiable data.

Protein Identification and Quantification

Protein identification is at the heart of most proteomics. This can be accomplished using MS or protein-specific capture/detecting reagents such as antibodies. Antibody detection and quantification of intact proteins has also been improving with the large-scale production of antibodies against human proteins by both industry and academia. Of note is the human protein atlas (<http://www.proteinatlas.org>), which currently has more than 13 150 antibodies that recognize gene products from 10 100 human genes.^{33,34} The use of antibody arrays (reversed or direct) provide the ability to screen for ever-increasing numbers of proteins, whereas the opposite, antigen arrays, can allow detection of autoantibodies (reviewed elsewhere^{35,36}). This work has stimulated the production of a new generation of affinity (capture and sensor [detecting]) reagents, including peptoids and aptamers (eg, see elsewhere^{37,38}).

MS is also a commonly used method that directly analyzes proteins or the respective peptides obtained via either enzymatic or chemical digestion. It is, however, the resulting peptides that provide amino acid sequence data. Although it is

often possible to deduce sequence information directly from the spectra, currently the most common data analysis pipelines include comparing the experimental spectra to those derived from a theoretical digestion (ie, *in silico*) of a selected protein database by way of a particular “search engine” algorithm (eg, Mascott, X!Tandem, Sequest, OSSMA). To ensure rigorous standards of data analysis and reporting, a number of important issues should be considered. First, the mass accuracy of the data affects the reliability of the identifications; therefore, the type of MS instrumentation used needs to be taken into consideration. Second, there are many different data search engine algorithms available, and each algorithm is likely to produce a different result from the same data. Third, many search engines will make some attempt to assign sequence information to poor quality spectra, which can result in incorrect identifications. Fourth, it is critical to select a protein database appropriate for the sample. Databases can vary with respect to accuracy and completeness, as well as contain protein name redundancy, whereby the same amino acid sequence may be represented by multiple accession numbers. Fifth, data clarity can be compromised if a spectrum can be assigned to multiple amino acid sequences, because of ambiguity, or if a peptide sequence can be assigned to multiple proteins, because of homology. Consequently, analysis of MS data and assignment of peptide/protein identification can be difficult.

Protein quantification is an important aspect of a proteomic analysis. There are essentially 2 types of quantification that are currently used in proteomics: relative ratio and absolute quantities. For the former, 2DE is most often used for proteins, whereas quantitation at the peptide level is achieved using metabolic (SILAC, on proliferating cells) or chemical labeling (most often labeling of the digested peptides include isobaric tag for relative and absolute quantification [also called iTRAQ³⁹]) and tandem mass tags (also called TMT⁴⁰) or label-free (based on spectral counts⁴¹). Comparison is made between 2 or more samples, allowing the relative quantitative relation between them to be determined. On the other hand, absolute quantification means that the precise value of each peptide or protein in a sample is determined independent of other samples. Previously, to obtain absolute quantitation of a protein, we were forced to rely on ELISA or quantitative Western blots, both of which require high-quality antibodies. When high-quality antibodies are available, these methods are very valuable. However, this is rare (although becoming less rare because of the large-scale efforts in reagent production as discussed previously) in research where candidate proteins arise from proteomic studies, or when specific protein isoforms (or specific modified amino acids) need to be investigated. With the recent adoption of multiple reaction monitoring (MRM), it is possible to obtain absolute quantification (relative ratios can also be determined) of target proteins without the need for antibodies. This MS method is a long-established technology in the field of metabolite quantification but has only in the last few years been optimized for the measurement of larger molecules, including peptides (eg, see elsewhere^{42–45}). In essence, a proteotypic peptide (an ionizable peptide with a unique amino acid sequence that is consistently observed by MS) that results from an enzymatic digestion of the

sample (eg, trypsin) is specifically selected within the MS instrument. MRM enhances: (1) protein studies across different species; (2) analysis when sample size is limited; (3) the study of proteins that have no (or poor quality) antibodies; (4) simultaneous quantification of multiple proteins (note upwards of 40 proteins in a single analysis⁴⁶); (5) quantification of protein isoforms; and (6) quantification of site-specific PTMs within one or more proteins (for review comparing ELISA and MRM, see elsewhere⁴⁷).

Targeted Analysis of PTMs

The area of PTM proteomics is challenging. Many PTMs are transient or labile with respect to MS analysis and are often present in low abundance, resulting in incomplete amino acid sequence coverage and a failure to fully characterize the PTMs. Biological complexity further impedes analysis; a single protein can have a number of amino acid residues that are modified, comprising one or different types of PTMs. Furthermore, each modified residue may have a different effect on function. Quantitative data on each modified amino acid residue are needed if we are to understand the dynamic changes of the proteome, the crosstalk and selectivity of different PTMs, and their impacts on signaling cascades. Many useful methods for PTM analysis have the following characteristics: (1) use enrichment of low-abundance modified proteins (or peptides); (2) simultaneously identify and quantify a protein; (3) identify the actual modified amino acid residue; (4) quantify the extent of a PTM under different conditions; and (5) quantify the relative differences of a particular modified residue in a protein with multiple modified residues. Most PTMs do not have such methods developed yet. Even so, progress has been made, either through the use of multiple methods, each allowing one to observe more of the PTM-proteome, or via a continuous refinement, often in incremental steps. Phosphorylation is an example where multiple synergistic approaches have been developed (reviewed elsewhere^{48–50}). It is (by far) the most common PTM described today (Figure 3). This PTM is of particular interest to the broader scientific community. The analysis of phosphoproteins can be done by multiple approaches, each with their own advantages and disadvantages. Often, 2DE is used because a change in pI of a protein in the first dimension can be indicative of phosphorylation (or dephosphorylation) attributable to the addition (or loss) of a charged phosphate group. However, a shift in pI can be attributable to a number of PTMs, and, hence, a secondary set of experiments is required to prove that the protein is phosphorylated. The treatment of the sample before 2DE with a phosphatase and monitoring the reverse shift in pI can be one unambiguous approach (eg, see elsewhere^{51,52}). However, a particular phosphatase (even those with broad specificity like alkaline phosphatases) does not dephosphorylate all proteins. Thus, if a protein does not show a shift after treatment this does not mean that the protein is not phosphorylated. ProQ diamond is a protein stain that displays enhanced binding to negatively charged proteins, like those which are phosphorylated.⁵³ However, false positives can occur thus secondary proof is required. The new phos-tag 1D gels can retard phosphorylated proteins and can provide insight in to extent of modifica-




Figure 3. The number of annotated human cardiac proteins with one or more different types of PTMs. The human protein reference database (currently contains 30 047 protein entries and 93 710 PTM sites) was searched for proteins that are known to be expressed in the heart. For this subgroup of proteins, all of the different PTMs annotated were determined (phosphorylation [combined with dephosphorylation]; acetylation, glycosylation [N- and O-linked, Glyc], proteolytic cleavage [Prot.Cl.], disulfide bridge [Disul. Br], ubiquitination, prenylation, sumoylation, myristoylation, and SNO). The number of different PTMs were determined and represented as a pie chart. The percentage of each PTM for those proteins that have only 1, 2, or 3 types of modifications are shown.

tion (most often based on western blots).⁵⁴ None of these protein based methods provides information about the actual phosphorylated amino acid residues. That requires additional MS analysis. To determine phospho-sites, there are also multiple techniques: direct analysis based on neutral loss and the phospho-peptide enrichment methods (immobilized metal affinity chromatography and TiO₂ affinity chromatography, among others). Importantly, each method sees only a subset of phospho-peptides. This means that it is difficult to unambiguously detect all phosphorylation sites in either an isolated protein or a complex protein mixture. Over the last few years, there has been considerable work defining the phosphoproteome within some of the subproteomes of cardiac muscle. This includes extensive analysis of the myofilament,⁵⁵ 20S proteasome,⁵⁶ and the mitochondria using both direct targeting of phospho-peptides⁵⁷ or proteins (eg, see elsewhere^{58–60}). However, none of these methods provides quantitative data without additional steps.

As mentioned above, in some cases, there is a continuous improvement of technology aimed at one particular problem. An example is the PTM, *O*-GlcNAcylation (*O*-GlcNAc), which was discovered more than 25 years ago

(see reference 61 and review reference 62). Today it is clear that *O*-GlcNAc rivals protein phosphorylation in terms of abundance, dynamic cycling, and distribution on nuclear, mitochondrial and cytoplasmic proteins.^{63–69} Within the heart this PTM has roles in aging, protection, and disease (eg, see references 70–76 and review references 77–79). However, this understanding was slow to be gained as GlcNAcylation is difficult to detect and quantify by standard methods and required continued technology development.^{80–83} The existing MS-based method can simultaneously quantify site occupancy for both *O*-GlcNAc and phosphate on hundreds of proteins (recent reviews^{84,85}). The interplay between these different types of PTM and the potential to influence the action of each other is becoming a more common theme not only for *O*-GlcNAc versus phosphorylation but also with other PTMs. For example, interplay between phosphorylation and SNO is also possible (eg, see elsewhere⁸⁶). SNO modification has been found for a number of phosphatases in a number of systems, although not yet in the heart. To follow up this and other PTM interplay in the future, technologies targeting less common PTMs will be essential. It is clear that this is an area of future growth.

Proteome Complexity

It is generally accepted that the proteome is complex and that some of this complexity arises from PTMs. To grapple with this, we have asked 2 questions: “What is the extent of PTMs reported in the human heart?” and “How many proteins have more than one type of PTM, a potential indication of signaling system crosstalk?” We turned to the well-annotated Human Protein Reference Database (HPRD) (www.hprd.org)⁸⁷ that was established by Dr Akhilesh Pandey (Johns Hopkins University). HPRD involves a large team of biologists, bioinformaticists, and software engineers who oversee and manually curate the information based on the literature with frequent reannotation. Our search was limited to only those human proteins that have been shown to be present in the heart. In total, there were 5079 human cardiac proteins annotated. Sixty-two percent of these have at least one documented PTM. For a breakdown regarding the number of proteins with a specific PTM and also heart proteins with specific cellular component/localization, see the upcoming review in this series. To investigate the potential for crosstalk between different types of signaling pathways that result in PTM, we determined the number of annotated human cardiac proteins with one or more different types of PTMs (Figure 3). Of these, a total of 3146 proteins, 75% have one PTM type. Phosphorylation dominates, accounting for more than 90% of all proteins with a single modification type. Not surprisingly, this is also true if the protein has more than one type of modification. It is somewhat surprising that acetylation is the next most prominent PTM in cardiac proteins followed by glycosylation (combing both *N*- and *O*-linked). There are a number of caveats to this information. The first, this database is only for human proteins (note: PTMs observed only in other species are not included). Second, the database is continuously being updated but only reflects what is present to date. Third, the information in the HPRD reflects only those proteins for which site data (the actual modified amino acid) is known. There has been continuous development of technological tools for the identification of phosphorylated amino acids residues, in part, driven by the wide interest in this particular PTM as a regulator of biological processes (as described above in the section Targeting the Analysis of PTMs). This has resulted in several studies identifying large number of phospho-sites in human cells or tissues. For example, recently 2225 phospho-sites were identified in 1023 proteins isolated from human liver,⁸⁸ whereas Mann and colleagues reported more than 20 000 phosphorylation sites in 6027 proteins from HeLa cells.⁸⁹ As tools are developed for other PTMs to allow easier determination of the actual modified amino acid residues, it will be very interesting to see how these numbers change.

Future Expanding Proteomic Coverage and Understanding

Although often inferred in protein identification, it is often difficult to distinguish specific protein isoforms, mutant or SNP and polymorphisms. This is most likely because of incomplete detection by the MS (a result of inherent sampling biased, ionizability of individual peptides, and instrument sensitivity thus reducing the coverage of a protein) and that

our bioinformatic tools and protein databases have yet to be sufficiently encompassing to allow the specific peptides to be identified. This is needed. In view of the great amount of data being generated from genomic studies (such as genome wide association studies [GWAS]) about SNPs and their link to human diseases, proteomic methods must move toward linking with this knowledge. Thus, more sensitive MS instruments, more robust methods to increase coverage (eg, enhanced protein and peptide separation and use of multiple enzymes), and expanded databases will help. One can envision means to specifically target disease-linked SNPs or mutations that would allow for quantification of the different forms. One possibility is MRM, because this is a peptide-based method. This level of proteome characterization will occur, but the method still needs to be refined in the “regular production stage” of development. Already, the triple quadrupole MS instruments are in clinical laboratories, where they are currently used for absolute quantification of metabolites and drugs. Thus, one can see a program development for protein/peptide based quantification of biomarkers in that setting.⁹⁰ However, what is needed is to move MRM into regular science research laboratories as a means to replace quantitative western blots and ELISA technology. The driving force will be the ability to greatly expand the number of analytes to quantify and to provide more accurate quantification with a larger dynamic range. To do this will require robust MS instruments that are user-friendly and a large number of consumables or kits comprising standard labeled peptides. The purchase of a MRM peptide kit for a particular protein, isoform, mutant, SNP, or PTM would be equivalent to the purchase of an antibody.

Equally important to the field of proteomics has been the simultaneous development of methods for large-scale protein characterization. These include initiatives in protein structure (eg, Protein Structure Initiative [PSI]; eg, reviewed^{91,92}), which currently it is feasible to determine the 3D structure of >100 proteins per year. There has also been a push to define protein interacting partners also referred to as the “interactome.” The interactome can target the identification of binding partners to a single protein but also can include the analysis of “complete” signaling cascades (eg, transforming growth factor β ⁹³), proteins that bind common small signaling molecules (eg, cAMP⁹⁴) or specific classes of proteins (eg, kinase/phosphatases⁹⁵). These studies on protein complexes have increased our understanding of basic protein biochemical properties, as well as pushed the field toward broad network analysis (eg, see elsewhere⁹⁶). Along these same lines, the biophysical protein characterization (eg, Structural Genomics Consortium [SGC]; reviewed elsewhere⁹⁷) and in vivo cell localization (reviewed elsewhere^{98,99}) are now being carried out in higher-throughput mode, although often in model systems.

Conclusions

Proteomics is becoming integrated and incorporated into cardiovascular research and, as such, will impact new discoveries. In this series, 4 articles are presented that provide concrete examples of how proteomics can be incorporated into research and address specific biological questions. Mayr

and colleagues present how proteomics has allowed a better definition of stem cell populations and their phenotype; Costello and colleagues have summarized the importance of oxidative modifications and their growing role and definition in cardiovascular disease; Agnetti et al discuss organelles and their interplay with PTM regulation, and, at the end, Gerzneten and colleagues describe the pipeline required to developed circulating biomarkers with clinical relevance. These articles summarize some novel aspects within cardiovascular research where proteomics has helped to provide solutions and insights into biology that would have been difficult without these approaches. Nonetheless, considerable roadblocks remain to fully integrate proteomics into cardiovascular research and translational medicine. As discussed in this review series, these include additional PTM-specific mapping tools, routine quantitative methods, more extensive databases, and more sensitive and cost effective instrumentation, to name a few. Furthermore, to exploit the proteomic data, we must find ways to integrate the data and the development of models to understand the complexity of the cell and organ. In addition, we need better approaches to link between a proteome change and direct function and cell localization in context to health and disease. Excitingly, however, technology does not stand still, and it will continue to undergo transformation, with older technologies improving and newer methods being developed. Proteomics research within the cardiovascular field is evolving rapidly, and if the past predicts the future, even more insights and novel findings will occur as the broader scientific community adopts and uses proteomic methods.

Acknowledgments

J.E.V.E. acknowledges Joe Coresh and Miroslava Stastna for thoughtful discussions, Cathrine Husberg for thoughtful discussions and work analyzing the cardiac proteome documented in the human protein reference database (HPRD), and A. Pandey for development of HPRD.

References

- Gundry RL, Tchernyshyov I, Sheng S, Tarasova Y, Raginski K, Boheler KR, Van Eyk JE. Expanding the mouse embryonic stem cell proteome: combining three proteomic approaches. *Proteomics*. 2010;10:2728–2732.
- Warren CM, Geenen DL, Helseth DL Jr, Xu H, Solaro RJ. Sub-proteomic fractionation, iTRAQ, and OFFGEL-LC-MS/MS approaches to cardiac proteomics. *J Proteomics*. 2010;73:1551–1561.
- Bousette N, Kislinger T, Fong V, Isserlin R, Hewel JA, Emil A, Gramolini AO. Large-scale characterization and analysis of the murine cardiac proteome. *J Proteome Res*. 2009;8:1887–1901.
- Callipo L, Capriotti AL, Cavaliere C, Gubbiotti R, Samperi R, Laganà A. Evaluation of different two-dimensional chromatographic techniques for proteomic analysis of mouse cardiac tissue. *Biomed Chromatogr*. 2010 Jul 22 [Epub ahead of print] PubMed PMID: 20652868.
- Duan X, Young R, Straubinger RM, Page B, Cao J, Wang H, Yu H, Canty JM, Qu J. A straightforward and highly efficient precipitation/on-pellet digestion procedure coupled with a long gradient nano-LC separation and Orbitrap mass spectrometry for label-free expression profiling of the swine heart mitochondrial proteome. *Proteome Res*. 2009;8:2838–2850.
- Drews O, Zong C, Ping P. Exploring proteasome complexes by proteomic approaches. *Proteomics*. 2007;7:1047–1058.
- Gomes AV, Zong C, Edmondson RD, Li X, Stefani E, Zhang J, Jones RC, Thyparambil S, Wang GW, Qiao X, Bardag-Gorce F, Ping P. Mapping the murine cardiac 26S proteasome complexes. *Circ Res*. 2006;99:362–371.
- Neverova I, Van Eyk JE. Application of reversed phase high performance liquid chromatography for subproteomic analysis of cardiac muscle. *Proteomics*. 2002;2:22–31.
- McDonald T, Sheng S, Stanley B, Chen D, Ko Y, Cole RN, Pedersen P, Van Eyk JE. Expanding the subproteome of the inner mitochondria using protein separation technologies: one- and two-dimensional liquid chromatography and two-dimensional gel electrophoresis. *Mol Cell Proteomics*. 2006;5:2392–2411.
- Taylor SW, Warnock DE, Glenn GM, Zhang B, Fahy E, Gaucher SP, Capaldi RA, Gibson BW, Ghosh SS. An alternative strategy to determine the mitochondrial proteome using sucrose gradient fractionation and 1D PAGE on highly purified human heart mitochondria. *J Proteome Res*. 2002;1:451–458.
- Ouyang Y, Mamidi R, Jayasundar JJ, Chandra M, Dong WJ. Structural and kinetic effects of PAK3 phosphorylation mimic of cTnI(S151E) on the cTnI-cTnI interaction in the cardiac thin filament. *J Mol Biol*. 2010;400:1036–1045.
- Sumandea MP, Rybin VO, Hinken AC, Wang C, Kobayashi T, Harleton E, Sievert G, Balke CW, Feinmark SJ, Solaro RJ, Steinberg SF. Tyrosine phosphorylation modifies protein kinase C delta-dependent phosphorylation of cardiac troponin I. *J Biol Chem*. 2008;283:22680–22689.
- Zabrouskov V, Ge Y, Schwartz J, Walker JW. Unraveling molecular complexity of phosphorylated human cardiac troponin I by top down electron capture dissociation/electron transfer dissociation mass spectrometry. *Mol Cell Proteomics*. 2008;7:1838–1849.
- Gallon CE. Current techniques for the study of troponin I phosphorylation in human heart. *J Muscle Res Cell Motil*. 2008;29:169–172.
- McDonough JL, Arrell DK, Van Eyk JE. Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. *Circ Res*. 1999;84:9–20.
- Feng J, Schaus BJ, Fallavollita JA, Lee TC, Canty JM Jr. Preload induces troponin I degradation independently of myocardial ischemia. *Circulation*. 2001;103:2035–2037.
- Ramirez-Correa GA, Jin W, Wang Z, Zhong X, Gao WD, Dias WB, Vecoli C, Hart GW, Murphy AM. O-linked GlcNAc modification of cardiac myofibrillar proteins: a novel regulator of myocardial contractile function. *Circ Res*. 2008;103:1354–1358.
- Kositprapa C, Zhang B, Berger S, Canty JM Jr, Lee TC. Calpain-mediated proteolytic cleavage of troponin I induced by hypoxia or metabolic inhibition in cultured neonatal cardiomyocytes. *Mol Cell Biochem*. 2000;214:47–55.
- Murphy AM, Kögler H, Georgakopoulos D, McDonough JL, Kass DA, Van Eyk JE, Marbán E. Transgenic mouse model of stunned myocardium. *Science*. 2000;287:488–491.
- Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. *Mol Cell Proteomics*. 2002;1:376–386.
- MacGillivray AJ, Rickwood D. The heterogeneity of mouse-chromatin nonhistone proteins as evidenced by two-dimensional polyacrylamide-gel electrophoresis and ion-exchange chromatography. *Eur J Biochem*. 1974;41:181–190.
- O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. *J Biol Chem*. 1975;250:4007–4021.
- Rabilloud T, Chevallet M, Luche S, Lelong C. Two-dimensional gel electrophoresis in proteomics: past, present and future. *J Proteomics*. 2010;73:2064–2077.
- Chevalier F. Highlights on the capacities of “gel-based” proteomics. *Proteome Sci*. 2010;8:23–26.
- Rabilloud T. Variations on a theme: changes to electrophoretic separations that can make a difference. *J Proteomics*. 2010;73:1562–1572.
- Friedman DB, Hoving S, Westermeier R, Westermeier R, Schickle H. The current state of the art in high-resolution two-dimensional electrophoresis. *Methods Enzymol*. 2009;463:305–328.
- Neverova I, Van Eyk JE. Role of chromatographic techniques in proteomic analysis. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2005;815:51–63.
- Horvatovich P, Hoekman B, Govorukhina N, Bischoff R. Multidimensional chromatography coupled to mass spectrometry in analysing complex proteomics samples. *J Sep Sci*. 2010;33:1421–1437.
- Tomás R, Klepárník K, Foret F. Multidimensional liquid phase separations for mass spectrometry. *J Sep Sci*. 2008;31:1964–1979.
- Mitulovic G, Mechtler K. HPLC techniques for proteomics analysis—a short overview of latest developments. *Brief Funct Genomic Proteomic*. 2006;5:249–260.

31. Guo Y, Ma SF, Grigoryev D, Van Eyk J, Garcia JG. 1-DE MS and 2-D LC-MS analysis of the mouse bronchoalveolar lavage proteome. *Proteomics*. 2005;5:4608–4624.
32. Sheng S, Chen D, Van Eyk JE. Multidimensional liquid chromatography separation of intact proteins by chromatographic focusing and reversed phase of the human serum proteome: optimization and protein database. *Mol Cell Proteomics*. 2006;5:26–34.
33. Berglund L, Björling E, Oksvold P, Fagerberg L, Asplund A, Szgyarto CA, Persson A, Ottosson J, Wernérus H, Nilsson P, Lundberg E, Sivertsson A, Navani S, Wester K, Kampf C, Hober S, Pontén F, Uhlén M. Gene-centric human protein atlas for expression profiles based on antibodies. *Mol Cell Proteomics*. 2008;7:2019–2027.
34. Nilsson P, Paavilainen L, Larsson K, Odling J, Sundberg M, Andersson AC, Kampf C, Persson A, Al-Khalili Szgyarto C, Ottosson J, Björling E, Hober S, Wernérus H, Wester K, Pontén F, Uhlén M. Towards a human proteome atlas: high-throughput generation of mono-specific antibodies for tissue profiling. *Proteomics*. 2005;5:4327–4337.
35. Voshol H, Ehrat M, Traenkli J, Bertrand E, van Oostrum. Antibody-based proteomics: analysis of signaling networks using reverse protein arrays. *J FEBS*. 2009;276:6871–6879.
36. Sharp V, Utz PJ. Technology insight: can autoantibody profiling improve clinical practice? *Nat Clin Pract Rheumatol*. 2007;3:96–103.
37. Uhlén M, Hober S. Generation and validation of affinity reagents on a proteome-wide level. *J Mol Recognit*. 2009;22:57–64.
38. Kodadek T. Synthetic receptors with antibody-like binding affinities. *Curr Opin Chem Biol*. 2010;4:713–720.
39. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlett-Jones M, He F, Jacobson A, Pappin DJ. Multiplexed protein quantitation in *Saccharomyces cerevisiae* using amine-reactive isobaric tagging reagents. *Mol Cell Proteomics*. 2004;3:1154–1169.
40. Thompson A, Schäfer J, Kuhn K, Kienle S, Schwarz J, Schmidt G, Neumann T, Johnstone R, Mohammed AK, Hamon C. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. *Anal Chem*. 2003;75:1895–1904.
41. Bantscheff M, Schirle M, Sweetman G, Rick J, Kuster B. Quantitative mass spectrometry in proteomics: a critical review. *Anal Bioanalytical Chem*. 2007;389:1017–1031.
42. Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2008;877:1229–1239.
43. Fortin T, Salvador A, Charrier JP, Lenz C, Lacoux X, Morla A, Choquet-Kastylevsky G, Lemoine J. Clinical quantitation of prostate specific antigen biomarker in the low nanogram/mL range by conventional bore liquid chromatography-tandem mass spectrometry (MRM) coupling and correlation with ELISA tests. *Mol Cell Proteomics*. 2009;8:1006–1015.
44. DeSouza LV, Taylor AM, Li W, Minkoff MS, Romaschin AD, Colgan TJ, Siu KW. Multiple reaction monitoring of mTRAQ-labeled peptides enables absolute quantification of endogenous levels of a potential cancer marker in cancerous and normal endometrial tissues. *J Proteome Res*. 2008;7:3525–3534.
45. Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and ¹³C-labeled peptide standards. *Proteomics*. 2004;4:1175–1186.
46. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. *Mol Cell Proteomics*. 2006;5:573–588.
47. Fu Q, Schoenhoff FS, Savage WJ, Zhang P, Van Eyk JE. Multiplex assays for biomarker research and clinical application: translational science coming of age. *Proteomics Clin Appl*. 2010;4:271–284.
48. Palmisano G, Thingholm TE. Strategies for quantitation of phosphoproteomic data. *Expert Rev Proteomics*. 2010;7:439–456.
49. Grimsrud PA, Swaney DL, Wenger CD, Beauchene NA, Coon JJ. Phosphoproteomics for the masses. *ACS Chem Biol*. 2010;5:105–119.
50. Lemeer S, Heck AJ. The phosphoproteomics data explosion. *Curr Opin Chem Biol*. 2009;13:414–420.
51. Agnetti G, Kaludercic N, Kane LA, Elliott ST, Guo Y, Chakir K, Samantapudi D, Paolucci N, Tomaselli GF, Kass DA, Van Eyk JE. Modulation of mitochondrial proteome and improved mitochondrial function by biventricular pacing of dyssynchronous failing hearts. *Circ Cardiovasc Genet*. 2010;3:78–87.
52. Matt P, Fu Z, Carrel T, Huso DL, Dirmhofer S, Lefkowitz I, Zerkowski HR, Van Eyk JE. Proteomic alterations in heat shock protein 27 and identification of phosphoproteins in ascending aortic aneurysm associated with bicuspid and tricuspid aortic valve. *J Mol Cell Cardiol*. 2007;43:792–801.
53. Martin K, Steinberg TH, Goodman T, Schulenberg B, Kilgore JA, Gee KR, Beechem JM, Patton WF. Strategies and solid-phase formats for the analysis of protein and peptide phosphorylation employing a novel fluorescent phosphorylation sensor dye. *Comb Chem High Throughput Screen*. 2003;6:331–339.
54. Kinoshita E, Kinoshita-Kikuta E, Takiyama K, Koike T. Phosphate-binding tag, a new tool to visualize phosphorylated proteins. *Mol Cell Proteomics*. 2006;5:749–757.
55. Yuan C, Sheng Q, Tang H, Li Y, Zeng R, Solaro RJ. Quantitative comparison of sarcomeric phosphoproteomes of neonatal and adult rat hearts. *Am J Physiol Heart Circ Physiol*. 2008;295:H647–H656.
56. Lu H, Zong C, Wang Y, Young GW, Deng N, Souda P, Li X, Whitelegge J, Drews O, Yang PY, Ping P. Revealing the dynamics of the 20 S proteasome phosphoproteome: a combined CID and electron transfer dissociation approach. *Mol Cell Proteomics*. 2008;7:2073–2089.
57. Deng N, Zhang J, Zong C, Wang Y, Lu H, Yang P, Wang W, Young GW, Wang Y, Korge P, Lotz C, Doran P, Liem DA, Apweiler R, Weiss JN, Duan H, Ping P. Phosphoproteome analysis reveals regulatory sites in major pathways of cardiac mitochondria. *Mol Cell Proteomics*. 2010 Sep 7 [Epub ahead of print] PubMed PMID: 20495213.
58. Aponte AM, Phillips D, Hopper RK, Johnson DT, Harris RA, Blinova K, Boja ES, French S, Balaban RS. Use of (32)P to study dynamics of the mitochondrial phosphoproteome. *J Proteome Res*. 2009;8:2679–2695.
59. Feng J, Zhu M, Schaub MC, Gehrig P, Roschitzki B, Lucchinetti E, Zaugg M. Phosphoproteome analysis of isoflurane-protected heart mitochondria: phosphorylation of adenine nucleotide translocator-1 on Tyr194 regulates mitochondrial function. *Cardiovasc Res*. 2008;80:20–29.
60. Chu G, Egnaczyk GF, Zhao W, Jo SH, Fan GC, Maggio JE, Xiao RP, Kranias EG. Phosphoproteome analysis of cardiomyocytes subjected to beta-adrenergic stimulation: identification and characterization of a cardiac heat shock protein p20. *Circ Res*. 2004;94:184–193.
61. Holt GD, Hart GW. The subcellular distribution of terminal N-acetylglucosamine moieties. Localization of a novel protein-saccharide linkage, O-linked GlcNAc. *J Biol Chem*. 1986;261:8049–8057.
62. Wells L, Hart GW. O-GlcNAc turns twenty: functional implications for post-translational modification of nuclear and cytosolic proteins with a sugar. *FEBS Lett*. 2003;546:154–158.
63. Ngoh GA, Hamid T, Prabhu SD, Jones SP. Increased O-linked beta-Nacetylglucosamine levels on proteins improves survival, reduces inflammation and organ damage 24 hours after trauma-hemorrhage in rats. *Am J Physiol Heart Circ Physiol*. 2009;297:H1711–H1719.
64. Wang Z, Gucek M, Hart GW. Cross-talk between GlcNAcylation and phosphorylation: site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc. *Proc Natl Acad Sci U S A*. 2008;105:13793–13798.
65. Copeland RJ, Bullen JW, Hart GW. Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity. *Am J Physiol Endocrinol Metab*. 2008;295:E17–E28.
66. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-Nacetylglucosamine on nucleocytoplasmic proteins. *Nature*. 2007;446:1017–1022.
67. Wang Z, Pandey A, Hart GW. Dynamic interplay between O-linked N-acetylglucosaminylation and glycogen synthase kinase-3-dependent phosphorylation. *Mol Cell Proteomics*. 2007;6:1365–1379.
68. Whelan SA, Lane MD, Hart GW. Regulation of the O-linked beta-Nacetylglucosamine transferase by insulin signaling. *J Biol Chem*. 2008;283:21411–21417.
69. Song M, Kim HS, Park JM, Kim SH, Kim IH, Ryu SH, Suh PG. O-GlcNAc transferase is activated by CaMKIV-dependent phosphorylation under potassium chloride-induced depolarization in NG-108-15 cells. *Cell Signal*. 2008;20:94–104.
70. Watson LJ, Facundo HT, Ngoh GA, Ameen M, Brainard RE, Lemma KM, Long BW, Prabhu SD, Xuan YT, Jones SP. O-linked N-acetylglucosamine transferase is indispensable in the failing heart. *Proc Natl Acad Sci U S A*. 2010;107:17797–17802.
71. Marsh SA, Dell'italia LJ, Chatham JC. Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic mice. *Amino Acids*. 2010 Jul 30 [Epub ahead of print] PubMed PMID: 20676904; PubMed Central PMCID: PMC3025273.
72. Yokoe S, Asahi M, Takeda T, Otsu K, Taniguchi N, Miyoshi E, Suzuki K. Inhibition of phospholamban phosphorylation by O-GlcNAcylation:

- implications for diabetic cardiomyopathy. *Glycobiology*. 2010;20:1217–1226.
73. Wu T, Zhou H, Jin Z, Bi S, Yang X, Yi D, Liu W. Cardioprotection of salidroside from ischemia/reperfusion injury by increasing N-acetylglucosamine linkage to cellular proteins. *Eur J Pharmacol*. 2009;613:93–99.
 74. Zou L, Yang S, Champattanachai V, Hu S, Chaudry IH, Marchase RB, Chatham JC. Glucosamine improves cardiac function following trauma-hemorrhage by increased protein O-GlcNAcylation and attenuation of NF- κ B signaling. *Am J Physiol Heart Circ Physiol*. 2009;296:H515–H523.
 75. Hu Y, Suarez J, Fricovsky E, Wang H, Scott BT, Trauger SA, Han W, Hu Y, Oyeleye MO, Dillmann WH. Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose. *J Biol Chem*. 2009;284:547–555.
 76. Fülöp N, Feng W, Xing D, He K, Not LG, Brocks CA, Marchase RB, Miller AP, Chatham JC. Aging leads to increased levels of protein O-linked N-acetylglucosamine in heart, aorta, brain and skeletal muscle in Brown-Norway rats. *Biogerontology*. 2008;9:139–151.
 77. Ngoh GA, Facundo HT, Zafir A, Jones SP. O-GlcNAc signaling in the cardiovascular system. *Circ Res*. 2010;107:171–185.
 78. Chatham JC, Marchase RB. The role of protein O-linked beta-N-acetylglucosamine in mediating cardiac stress responses. *Biochim Biophys Acta*. 2010;1800:57–66.
 79. Lacy B, Hill BG, Wang K, Paterson AJ, White CR, Xing D, Chen YF, Darley-Usmar V, Oparil S, Chatham JC. Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. *Am J Physiol Heart Circ Physiol*. 2009;296:H13–H28.
 80. Rexach JE, Rogers CJ, Yu SH, Tao J, Sun YE, Hsieh-Wilson LC. Quantification of O-glycosylation stoichiometry and dynamics using resolvable mass tags. *Nat Chem Biol*. 2010;6:645–651.
 81. Wang Z, Udeshi ND, O'Malley M, Shabanowitz J, Hunt DF, Hart GW. Enrichment and site mapping of O-linked N-acetylglucosamine by a combination of chemical/enzymatic tagging, photochemical cleavage, and electron transfer dissociation mass spectrometry. *Mol Cell Proteomics*. 2010;9:153–160.
 82. Zachara NE, Cole RN, Hart GW, Gao Y. Detection and analysis of proteins modified by O-linked N-acetylglucosamine. *Curr Protoc Protein Sci*. 2001;Chapter 12:Unit 12.8.
 83. Wells L, Vosseller K, Cole RN, Cronshaw JM, Matunis MJ, Hart GW. Mapping sites of O-GlcNAc modification using affinity tags for serine and threonine post-translational modifications. *Mol Cell Proteomics*. 2002;1:791–804.
 84. Hu P, Shimoji S, Hart GW. Site-specific interplay between O-GlcNAcylation and phosphorylation in cellular regulation. *Mol Biol Cell*. 2010;21:1922–1936.
 85. Zeidan Q, Hart GW. The intersections between O-GlcNAcylation and phosphorylation: implications for multiple signaling pathways. *J Cell Sci*. 2010;123:13–22.
 86. Foster DB, Van Eyk JE, Marbán E, O'Rourke B. Redox signaling and protein phosphorylation in mitochondria: progress and prospects. *J Bioenerg Biomembr*. 2009;41:159–168.
 87. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A, Balakrishnan L, Marimuthu A, Banerjee S, Somanathan DS, Sebastian A, Rani S, Ray S, Harrys Kishore CJ, Kanth S, Ahmed M, Kashyap MK, Mohmood R, Ramachandra YL, Krishna V, Rahiman BA, Mohan S, Ranganathan P, Ramabadran S, Chaerkady R, Pandey A. Human Protein Reference Database–2009 Update. *Nucleic Acids Research*. 2009;37:D767–D772.
 88. Han G, Ye M, Liu H, Song C, Sun D, Wu Y, Jiang X, Chen R, Wang C, Wang L, Zou H. Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. *Electrophoresis*. 2010;31:1080–1089.
 89. Olsen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, Jensen LJ, Gnad F, Cox J, Jensen TS, Nigg EA, Brunak S, Mann M. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. *Sci Signal*. 2010;3:ra3.
 90. Patterson SD, Van Eyk JE, Banks RE. Report from the Wellcome Trust/EBA “Perspectives in Clinical Proteomics” retreat—a strategy to implement next-generation proteomic analyses to the clinic for patient benefit: pathway to translation. *Proteomics Clin Appl*. 2010;4:883–887.
 91. Edwards A. Large-scale structural biology of the human proteome. *Annu Rev Biochem*. 2009;78:541–568.
 92. Terwilliger TC, Stuart D, Yokoyama S. Lessons from structural genomics. *Annu Rev Biophys*. 2009;38:371–383.
 93. Perera M, Tsang CS, Distel RJ, Lacy JN, Ohno-Machado L, Ricchiuti V, Samaranayake LP, Smejkal GB, Smith MG, Trachtenberg AJ, Kuo WP. TGF-beta1 interactome: metastasis and beyond. *Cancer Genomics Proteomics*. 2010;7:217–229.
 94. Scholten A, Poh MK, van Veen TA, van Breukelen B, Vos MA, Heck AJ. cAMP interactome using a chemical proteomics approach in mammalian heart tissue validates sphingosine kinase type 1-interacting protein as a genuine and highly abundant AKAP. *J Proteome Res*. 2006;5:1435–1447.
 95. Roy J, Cyert MS. Cracking the phosphatase code: docking interactions determine substrate specificity. *Sci Signal*. 2009;2:re9.
 96. De Las Rivas J, de Luis A. Interactome data and databases: different types of protein interaction. *Comp Funct Genomics*. 2004;5:173–178.
 97. Vedadi M, Arrowsmith CH, Allali-Hassani A, Senisterra G, Wasney GA. Biophysical characterization of recombinant proteins: a key to higher structural genomics success. *J Struct Biol*. 2010;172:107–119.
 98. Fero M, Pogliano K. Automated quantitative live cell fluorescence microscopy. *Cold Spring Harb Perspect Biol*. 2010;2:a000455.
 99. Hamilton NA, Teasdale RD. Visualizing and clustering high throughput sub-cellular localization imaging. *BMC Bioinformatics*. 2008;9:81.

Circulation Research

JOURNAL OF THE AMERICAN HEART ASSOCIATION



Overview: The Maturing of Proteomics in Cardiovascular Research Jennifer E. Van Eyk

Circ Res. 2011;108:490-498

doi: 10.1161/CIRCRESAHA.110.226894

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2011 American Heart Association, Inc. All rights reserved.

Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the
World Wide Web at:

<http://circres.ahajournals.org/content/108/4/490>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation Research* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Circulation Research* is online at:
<http://circres.ahajournals.org/subscriptions/>